Non-alcoholic Fatty Liver Disease (NAFLD) Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Non-alcoholic Fatty Liver Disease (NAFLD) Epidemiology Forecast Report Coverage

Expert Market Research's “Non-alcoholic Fatty Liver Disease (NAFLD) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of non-alcoholic fatty liver disease (NAFLD). It projects the future incidence and prevalence rates of non-alcoholic fatty liver disease (NAFLD) cases across various populations. The study covers age, gender, and type as major determinants of the non-alcoholic fatty liver disease (NAFLD) population. The report highlights patterns in the prevalence of non-alcoholic fatty liver disease (NAFLD) over time and projects future trends based on multiple variables.

Non-alcoholic Fatty Liver Disease (NAFLD) Understanding: Disease Overview

Non-alcoholic fatty liver disease (NAFLD), now referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), is characterized by excess fat accumulation in the liver, reflecting rising fatty liver disease prevalence worldwide. The condition ranges from simple steatosis to progressive inflammation, fibrosis, and liver damage. Risk factors include obesity, type 2 diabetes, dyslipidemia, hypertension, and metabolic syndrome, while symptoms may include fatigue, abdominal discomfort, jaundice, and unintended weight loss.

Non-alcoholic Fatty Liver Disease (NAFLD) Epidemiology Perspective

The non-alcoholic fatty liver disease (NAFLD) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the non-alcoholic fatty liver disease (NAFLD) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for non-alcoholic fatty liver disease (NAFLD) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Ravichandran et al. (2025), approximately 38% of the global population is affected by non-alcoholic fatty liver disease (NAFLD), highlighting a substantial non-alcoholic fatty liver disease burden driven by obesity, unhealthy diets, and sedentary lifestyles.
• According to Estes et al., the prevalence of NAFLD is projected to reach 33.5% by 2030, indicating worsening non-alcoholic fatty liver disease epidemiology trends and increasing healthcare challenges.
• According to Meda et al. (2024), around 18% of pregnant women are affected by non-alcoholic fatty liver disease (NAFLD), with hormonal and metabolic changes contributing to disease progression and influencing risk distribution across populations.

Read more about this report - Request a Free Sample

Country-wise Non-alcoholic Fatty Liver Disease (NAFLD) Epidemiology

The non-alcoholic fatty liver disease (NAFLD) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

According to Shalimar et al., the epidemiology of non-alcoholic fatty liver disease (NAFLD) varies across countries due to differences in metabolic risk factors, lifestyle patterns, genetic predisposition, and healthcare access, reflecting notable NAFLD regional prevalence variations. The study reported that over one-third (38%) of the Indian population is affected by fatty liver or NAFLD, highlighting a substantial and growing disease burden. Additionally, Younossi et al. (2024) reported in a PubMed Central-indexed study that the rising global NAFLD burden is driven by increasing obesity, metabolic syndrome, and sedentary behavior worldwide.

Non-alcoholic Fatty Liver Disease (NAFLD): Treatment Overview

The treatment of NAFLD primarily focuses on lifestyle modification, aligning with evolving metabolic liver disease epidemiology insights. Patients are advised to adopt a balanced diet and regular physical activity, with a recommended 5-10% weight reduction to improve hepatic outcomes. Pharmacological interventions include statins for dyslipidemia and fibrates for elevated triglycerides. These approaches aim to reduce liver fat accumulation, inflammation, and associated metabolic complications.

Key Questions Answered

• What are the key findings of non-alcoholic fatty liver disease (NAFLD) epidemiology in the 8 major markets?
• What will be the total number of patients with non-alcoholic fatty liver disease (NAFLD) across the 8 major markets during the forecast period?
• What was the country-wise non-alcoholic fatty liver disease (NAFLD) epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of non-alcoholic fatty liver disease (NAFLD) patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of non-alcoholic fatty liver disease (NAFLD) during the forecast period of 2026-2035?
• What are the currently available treatments for non-alcoholic fatty liver disease (NAFLD)?
• What are the disease risks, signs, symptoms, and unmet needs of non-alcoholic fatty liver disease (NAFLD)?

Scope of the Non-alcoholic Fatty Liver Disease (NAFLD) Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of non-alcoholic fatty liver disease (NAFLD) based on several factors.
• Non-alcoholic Fatty Liver Disease (NAFLD) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The non-alcoholic fatty liver disease (NAFLD) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Liver Disease Treatment Market

Liver Cancer Therapeutics Market